TKIs are the first-line treatment for NSCLC, though resistance can develop due to hyperactivation or mutations in a variety of oncogenic proteins (in various cancers), including EGFR, fibroblast growth factor receptor, BRAF, MET, Anaplastic lymphoma kinase, vascular endothelial growth factor receptor (VEGFR), and tyrosine-protein kinase Src [54,55,56]. This evidence concerns the gene KDR and cancer.